Share on StockTwits

Adamas Pharmaceuticals (NASDAQ:ADMS) issued its quarterly earnings data on Thursday. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.81 by $0.07, Analyst Ratings News reports. The company had revenue of $25.15 million for the quarter, compared to the consensus estimate of $18.75 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 2.96% on Thursday, hitting $15.71. 15,676 shares of the company’s stock traded hands. Adamas Pharmaceuticals has a one year low of $12.02 and a one year high of $21.63. The stock’s 50-day moving average is $17.21 and its 200-day moving average is $17.52. The company has a market cap of $262.5 million and a P/E ratio of 8.17.

Adamas Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson’s disease known as levodopa induced dyskinesia (NASDAQ:ADMS), and as a treatment for chronic behavioral symptoms associated with traumatic brain injury (TBI).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.